Alpine Immune Sciences (NASDAQ:ALPN) Receives Hold Rating from TD Cowen

TD Cowen restated their hold rating on shares of Alpine Immune Sciences (NASDAQ:ALPN) in a report published on Tuesday morning, Benzinga reports.

Several other analysts have also commented on the stock. Guggenheim began coverage on shares of Alpine Immune Sciences in a research report on Tuesday, April 9th. They set a buy rating and a $55.00 price target for the company. Oppenheimer reissued an outperform rating and set a $44.00 price target (up from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. Wedbush lowered shares of Alpine Immune Sciences from an outperform rating to a neutral rating in a research report on Thursday, April 11th. Wolfe Research reissued a peer perform rating on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Finally, Morgan Stanley reaffirmed an equal weight rating and issued a $65.00 price objective (up from $47.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Eight investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Alpine Immune Sciences currently has a consensus rating of Hold and an average price target of $50.33.

Alpine Immune Sciences Price Performance

NASDAQ:ALPN opened at $64.50 on Tuesday. Alpine Immune Sciences has a 1-year low of $6.71 and a 1-year high of $64.57. The company has a 50-day moving average of $37.92 and a 200 day moving average of $23.86. The firm has a market cap of $4.23 billion, a PE ratio of -100.78 and a beta of 1.14.

Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The company had revenue of $30.85 million during the quarter, compared to analyst estimates of $6.90 million. Sell-side analysts anticipate that Alpine Immune Sciences will post -1.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Alpine Immune Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada increased its holdings in Alpine Immune Sciences by 99.1% in the 2nd quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock worth $27,000 after buying an additional 1,315 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in Alpine Immune Sciences by 745.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,312 shares during the period. Public Employees Retirement System of Ohio acquired a new position in Alpine Immune Sciences in the 3rd quarter worth approximately $35,000. Barclays PLC increased its holdings in Alpine Immune Sciences by 818.4% in the 4th quarter. Barclays PLC now owns 6,080 shares of the biotechnology company’s stock worth $45,000 after buying an additional 5,418 shares during the period. Finally, BNP Paribas Arbitrage SNC increased its holdings in Alpine Immune Sciences by 88.7% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 6,572 shares of the biotechnology company’s stock worth $47,000 after buying an additional 3,090 shares during the period. Institutional investors and hedge funds own 75.17% of the company’s stock.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.